<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20240926205110
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20240926205110" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 27 Sep 2024 00:51:11 +0000</lastbuilddate>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Metabolic and Shear Stress Regulate Endothelial Epas1 in Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325850/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27;135(8):838-840. doi: 10.1161/CIRCRESAHA.124.325131. Epub 2024 Sep 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325850/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325850</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325131>10.1161/CIRCRESAHA.124.325131</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325850</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith C Sluimer</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Metabolic and Shear Stress Regulate Endothelial Epas1 in Atherosclerosis</dc:title>
<dc:identifier>pmid:39325850</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325131</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325848/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27;135(8):804-805. doi: 10.1161/RES.0000000000000694. Epub 2024 Sep 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325848</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000694>10.1161/RES.0000000000000694</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325848</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39325848</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000694</dc:identifier>
</item>
<item>
<title>Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA Drugs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>All Food and Drug Administration-approved noncoding RNA (ncRNA) drugs (n≈20) target known disease-causing molecular pathways by mechanisms such as antisense. In a fortuitous evolution of work on regenerative medicine, my coworkers and I inverted the RNA drug discovery process: first we identified natural disease-modifying ncRNAs, then used them as templates for new synthetic RNA drugs. Mechanism was probed only after bioactivity had been demonstrated. The journey began with the development of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 27;135(8):877-885. doi: 10.1161/CIRCRESAHA.124.323058. Epub 2024 Sep 26.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">All Food and Drug Administration-approved noncoding RNA (ncRNA) drugs (n≈20) target known disease-causing molecular pathways by mechanisms such as antisense. In a fortuitous evolution of work on regenerative medicine, my coworkers and I inverted the RNA drug discovery process: first we identified natural disease-modifying ncRNAs, then used them as templates for new synthetic RNA drugs. Mechanism was probed only after bioactivity had been demonstrated. The journey began with the development of cardiosphere-derived cells (CDCs) for cardiac regeneration. While testing CDCs in a first-in-human trial, we discovered they worked indirectly: ncRNAs within CDC-secreted extracellular vesicles mediate the therapeutic benefits. The vast majority of such ncRNAs are fragments of unknown function. We chose several abundant ncRNA species from CDC-secreted extracellular vesicles, synthesized and screened each of them in vitro and in vivo. Those with exceptional disease-modifying bioactivity inspired new chemical entities that conform to the structural conventions of the Food and Drug Administration-approved ncRNA armamentarium. This discovery arc-Cell-Derived RNA from Extracellular vesicles for bioinspired Drug develOpment, or CREDO-has yielded various promising lead compounds, each of which works via a unique, and often novel, mechanism. The process relies on emergent insights to shape therapeutic development. The initial focus of our inquiry-CDCs-are now themselves in phase 3 testing for Duchenne muscular dystrophy and its associated cardiomyopathy. But the intravenous delivery strategy and the repetitive dosing protocol for CDCs, which have proven key to clinical success, both arose from systematic mechanistic inquiry. Meanwhile, emergent insights have led to multiple cell-free therapeutic candidates: CDC-secreted extracellular vesicles are in preclinical development for ventricular arrhythmias, while the CREDO-conceived RNA drugs are in translation for diseases ranging from myocarditis to scleroderma.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325847</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323058>10.1161/CIRCRESAHA.124.323058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325847</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Eduardo Marbán</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA Drugs</dc:title>
<dc:identifier>pmid:39325847</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323058</dc:identifier>
</item>
<item>
<title>Colchicine and Atherothrombosis: Another Piece of the Puzzle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325503/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24;150(13):994-996. doi: 10.1161/CIRCULATIONAHA.124.071344. Epub 2024 Sep 23.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325503/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325503</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071344>10.1161/CIRCULATIONAHA.124.071344</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325503</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Brittany Weber</dc:creator>
<dc:creator>Antonio Abbate</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Colchicine and Atherothrombosis: Another Piece of the Puzzle</dc:title>
<dc:identifier>pmid:39325503</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071344</dc:identifier>
</item>
<item>
<title>Response by Giacoppo et al to Letter Regarding Article "Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24;150(13):e271-e272. doi: 10.1161/CIRCULATIONAHA.124.071021. Epub 2024 Sep 23.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325501</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071021>10.1161/CIRCULATIONAHA.124.071021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325501</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Claudio Laudani</dc:creator>
<dc:creator>Giovanni Occhipinti</dc:creator>
<dc:creator>Marco Spagnolo</dc:creator>
<dc:creator>Antonio Greco</dc:creator>
<dc:creator>Carla Rochira</dc:creator>
<dc:creator>Federica Agnello</dc:creator>
<dc:creator>Davide Landolina</dc:creator>
<dc:creator>Maria Sara Mauro</dc:creator>
<dc:creator>Simone Finocchiaro</dc:creator>
<dc:creator>Placido Maria Mazzone</dc:creator>
<dc:creator>Nicola Ammirabile</dc:creator>
<dc:creator>Antonino Imbesi</dc:creator>
<dc:creator>Carmelo Raffo</dc:creator>
<dc:creator>Sergio Buccheri</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Giacoppo et al to Letter Regarding Article "Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis"</dc:title>
<dc:identifier>pmid:39325501</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071021</dc:identifier>
</item>
<item>
<title>Letter by Zhang Regarding Article, "Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24;150(13):e269-e270. doi: 10.1161/CIRCULATIONAHA.124.069731. Epub 2024 Sep 23.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325500</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069731>10.1161/CIRCULATIONAHA.124.069731</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325500</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Zaiyong Zhang</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang Regarding Article, "Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis"</dc:title>
<dc:identifier>pmid:39325500</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069731</dc:identifier>
</item>
<item>
<title>Heterogeneity of Treatment Effects in Clinical Trials: Overview of Multivariable Approaches and Practical Recommendations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325499/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24;150(13):978-980. doi: 10.1161/CIRCULATIONAHA.124.069857. Epub 2024 Sep 23.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325499/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325499</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069857>10.1161/CIRCULATIONAHA.124.069857</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325499</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Heterogeneity of Treatment Effects in Clinical Trials: Overview of Multivariable Approaches and Practical Recommendations</dc:title>
<dc:identifier>pmid:39325499</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069857</dc:identifier>
</item>
<item>
<title>Kidney Disease as a Cardiovascular Disease Priority</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325498/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24;150(13):975-977. doi: 10.1161/CIRCULATIONAHA.124.068242. Epub 2024 Sep 23.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325498/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325498</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068242>10.1161/CIRCULATIONAHA.124.068242</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325498</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sradha S Kotwal</dc:creator>
<dc:creator>Vlado Perkovic</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Kidney Disease as a Cardiovascular Disease Priority</dc:title>
<dc:identifier>pmid:39325498</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068242</dc:identifier>
</item>
<item>
<title>Immunomodulatory Therapy for Ischemic Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325497/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>Ischemic heart disease is a leading cause of death worldwide, manifested clinically as myocardial infarction (and ischemic cardiomyopathy. Presently, there exists a notable scarcity of efficient interventions to restore cardiac function after myocardial infarction. Cumulative evidence suggests that impaired tissue immunity within the ischemic microenvironment aggravates cardiac dysfunction, contributing to progressive heart failure. Recent research breakthroughs propose immunotherapy as a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24;150(13):1050-1058. doi: 10.1161/CIRCULATIONAHA.124.070368. Epub 2024 Sep 23.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ischemic heart disease is a leading cause of death worldwide, manifested clinically as myocardial infarction (and ischemic cardiomyopathy. Presently, there exists a notable scarcity of efficient interventions to restore cardiac function after myocardial infarction. Cumulative evidence suggests that impaired tissue immunity within the ischemic microenvironment aggravates cardiac dysfunction, contributing to progressive heart failure. Recent research breakthroughs propose immunotherapy as a potential approach by leveraging immune and stroma cells to recalibrate the immune microenvironment, holding significant promise for the treatment of ischemic heart disease. In this Primer, we highlight three emerging strategies for immunomodulatory therapy in managing ischemic cardiomyopathy: targeting vascular endothelial cells to rewire tissue immunity, reprogramming myeloid cells to bolster their reparative function, and utilizing adoptive T cell therapy to ameliorate fibrosis. We anticipate that immunomodulatory therapy will offer exciting opportunities for ischemic heart disease treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325497/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325497</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070368>10.1161/CIRCULATIONAHA.124.070368</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325497</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xinye Zhao</dc:creator>
<dc:creator>Thomas Williamson</dc:creator>
<dc:creator>Yanqing Gong</dc:creator>
<dc:creator>Jonathan A Epstein</dc:creator>
<dc:creator>Yi Fan</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Immunomodulatory Therapy for Ischemic Heart Disease</dc:title>
<dc:identifier>pmid:39325497</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070368</dc:identifier>
</item>
<item>
<title>ECG Changes in a Patient With Recurrent Palpitations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39325496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24;150(13):1061-1063. doi: 10.1161/CIRCULATIONAHA.124.071468. Epub 2024 Sep 23.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39325496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39325496</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071468>10.1161/CIRCULATIONAHA.124.071468</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39325496</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kapil Rajendran</dc:creator>
<dc:creator>Arun Jude Alphonse</dc:creator>
<dc:creator>Vinayakumar Desabandhu</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>ECG Changes in a Patient With Recurrent Palpitations</dc:title>
<dc:identifier>pmid:39325496</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071468</dc:identifier>
</item>
<item>
<title>Associations of "Weekend Warrior" Physical Activity With Incident Disease and Cardiometabolic Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39324186/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Achievement of measured physical activity volumes consistent with guideline recommendations is associated with lower risk for >;200 diseases, with prominent effects on cardiometabolic conditions. Associations appear similar whether physical activity follows a weekend warrior pattern or is spread more evenly throughout the week.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 26. doi: 10.1161/CIRCULATIONAHA.124.068669. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Achievement of guideline-recommended levels of physical activity (≥150 minutes of moderate-to-vigorous physical activity per week) is associated with lower risk of adverse cardiovascular events and represents an important public health priority. Although physical activity commonly follows a "weekend warrior" pattern, in which most moderate-to-vigorous physical activity is concentrated in 1 or 2 days rather than spread more evenly across the week (regular), the effects of physical activity pattern across a range of incident diseases, including cardiometabolic conditions, are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We tested associations between physical activity pattern and incidence of 678 conditions in 89 573 participants (62±8 years of age; 56% women) of the UK Biobank prospective cohort study who wore an accelerometer for 1 week between June 2013 and December 2015. Models were adjusted for multiple baseline clinical factors, and <i>P</i> value thresholds were corrected for multiplicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: When compared to inactive (&lt;150 minutes moderate-to-vigorous physical activity/week), both weekend warrior (267 total associations; 264 [99%] with lower disease risk; hazard ratio [HR] range, 0.35-0.89) and regular activity (209 associations; 205 [98%] with lower disease risk; HR range, 0.41-0.88) were broadly associated with lower risk of incident disease. The strongest associations were observed for cardiometabolic conditions such as incident hypertension (weekend warrior: HR, 0.77 [95% CI, 0.73-0.80]; <i>P</i>=1.2×10<sup>-27</sup>; regular: HR, 0.72 [95% CI, 0.68-0.77]; <i>P</i>=4.5×10<sup>-28</sup>), diabetes (weekend warrior: HR, 0.57 [95% CI, 0.51-0.62]; <i>P</i>=3.9×10<sup>-32</sup>; regular: HR, 0.54 [95% CI, 0.48-0.60]; <i>P</i>=8.7×10<sup>-26</sup>), obesity (weekend warrior: HR, 0.55 [95% CI, 0.50-0.60]; <i>P</i>=2.4×10<sup>-43</sup>, regular: HR, 0.44 [95% CI, 0.40-0.50]; <i>P</i>=9.6×10<sup>-47</sup>), and sleep apnea (weekend warrior: HR, 0.57 [95% CI, 0.48-0.69]; <i>P</i>=1.6×10<sup>-9</sup>; regular: HR, 0.49 [95% CI, 0.39-0.62]; <i>P</i>=7.4×10<sup>-10</sup>). When weekend warrior and regular activity were compared directly, there were no conditions for which effects differed significantly. Observations were similar when activity was thresholded at the sample median (≥230.4 minutes of moderate-to-vigorous physical activity/week).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Achievement of measured physical activity volumes consistent with guideline recommendations is associated with lower risk for >;200 diseases, with prominent effects on cardiometabolic conditions. Associations appear similar whether physical activity follows a weekend warrior pattern or is spread more evenly throughout the week.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39324186/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39324186</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068669>10.1161/CIRCULATIONAHA.124.068669</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39324186</guid>
<pubDate>Thu, 26 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Mostafa A Al-Alusi</dc:creator>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>James P Pirruccello</dc:creator>
<dc:creator>Timothy W Churchill</dc:creator>
<dc:creator>Steven A Lubitz</dc:creator>
<dc:creator>Mahnaz Maddah</dc:creator>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:date>2024-09-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations of "Weekend Warrior" Physical Activity With Incident Disease and Cardiometabolic Health</dc:title>
<dc:identifier>pmid:39324186</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068669</dc:identifier>
</item>
<item>
<title>Intravascular ultrasound improves the outcomes of drug-coated balloon angioplasty by providing precise vessel dimensions for optimal device size selection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322939/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 25:ehae622. doi: 10.1093/eurheartj/ehae622. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322939/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322939</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae622>10.1093/eurheartj/ehae622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322939</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Young-Guk Ko</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravascular ultrasound improves the outcomes of drug-coated balloon angioplasty by providing precise vessel dimensions for optimal device size selection</dc:title>
<dc:identifier>pmid:39322939</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae622</dc:identifier>
</item>
<item>
<title>The burden of atrial fibrillation in the Asia-Pacific region</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 25. doi: 10.1038/s41569-024-01091-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322762</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01091-1>10.1038/s41569-024-01091-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322762</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Christopher X Wong</dc:creator>
<dc:creator>Hung Fat Tse</dc:creator>
<dc:creator>Eue-Kuen Choi</dc:creator>
<dc:creator>Tze-Fan Chao</dc:creator>
<dc:creator>Koichi Inoue</dc:creator>
<dc:creator>Katrina Poppe</dc:creator>
<dc:creator>Eugene Tan</dc:creator>
<dc:creator>Yoga Yuniadi</dc:creator>
<dc:creator>Erdie Fadreguilan</dc:creator>
<dc:creator>Sofian Johar</dc:creator>
<dc:creator>Ngai Yin Chan</dc:creator>
<dc:creator>Narayan Namboodiri</dc:creator>
<dc:creator>S Mokaddas Hossain</dc:creator>
<dc:creator>Huang He</dc:creator>
<dc:creator>Thoranis Chantrarat</dc:creator>
<dc:creator>Abdul Raqib Bin Abd Ghani</dc:creator>
<dc:creator>Narantuya Davaakhuu</dc:creator>
<dc:creator>Nwe Nwe</dc:creator>
<dc:creator>Ghazala Irfan</dc:creator>
<dc:creator>Minh That Ton</dc:creator>
<dc:creator>Rohan Gunawardena</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The burden of atrial fibrillation in the Asia-Pacific region</dc:title>
<dc:identifier>pmid:39322762</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01091-1</dc:identifier>
</item>
<item>
<title>Cardiovascular care with digital twin technology in the era of generative artificial intelligence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322420/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>Digital twins, which are in silico replications of an individual and its environment, have advanced clinical decision-making and prognostication in cardiovascular medicine. The technology enables personalized simulations of clinical scenarios, prediction of disease risk, and strategies for clinical trial augmentation. Current applications of cardiovascular digital twins have integrated multi-modal data into mechanistic and statistical models to build physiologically accurate cardiac replicas to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 26:ehae619. doi: 10.1093/eurheartj/ehae619. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Digital twins, which are in silico replications of an individual and its environment, have advanced clinical decision-making and prognostication in cardiovascular medicine. The technology enables personalized simulations of clinical scenarios, prediction of disease risk, and strategies for clinical trial augmentation. Current applications of cardiovascular digital twins have integrated multi-modal data into mechanistic and statistical models to build physiologically accurate cardiac replicas to enhance disease phenotyping, enrich diagnostic workflows, and optimize procedural planning. Digital twin technology is rapidly evolving in the setting of newly available data modalities and advances in generative artificial intelligence, enabling dynamic and comprehensive simulations unique to an individual. These twins fuse physiologic, environmental, and healthcare data into machine learning and generative models to build real-time patient predictions that can model interactions with the clinical environment to accelerate personalized patient care. This review summarizes digital twins in cardiovascular medicine and their potential future applications by incorporating new personalized data modalities. It examines the technical advances in deep learning and generative artificial intelligence that broaden the scope and predictive power of digital twins. Finally, it highlights the individual and societal challenges as well as ethical considerations that are essential to realizing the future vision of incorporating cardiology digital twins into personalized cardiovascular care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322420/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322420</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae619>10.1093/eurheartj/ehae619</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322420</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Phyllis M Thangaraj</dc:creator>
<dc:creator>Sean H Benson</dc:creator>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Folkert W Asselbergs</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular care with digital twin technology in the era of generative artificial intelligence</dc:title>
<dc:identifier>pmid:39322420</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae619</dc:identifier>
</item>
<item>
<title>Catheter ablation for atrial fibrillation: indications and future perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>Recent advances in techniques, technologies and proven superiority over anti-arrhythmic drugs have made catheter ablation the cornerstone of management for atrial fibrillation (AF), which has shown a steady increase in prevalence in the ageing population worldwide. The aim of therapeutic interventions is to achieve stable sinus rhythm that would improve the quality of life and reduce the risk of AF-associated complications. Pulmonary veins (PVs) were first described as the source of initiation...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 26:ehae618. doi: 10.1093/eurheartj/ehae618. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent advances in techniques, technologies and proven superiority over anti-arrhythmic drugs have made catheter ablation the cornerstone of management for atrial fibrillation (AF), which has shown a steady increase in prevalence in the ageing population worldwide. The aim of therapeutic interventions is to achieve stable sinus rhythm that would improve the quality of life and reduce the risk of AF-associated complications. Pulmonary veins (PVs) were first described as the source of initiation of ectopic triggers driving AF, which led to the establishment of PV isolation (PVI) as the most widely practiced procedure to treat AF. Antral PVI is still recognized as the stand-alone ablation strategy for newly diagnosed paroxysmal AF (PAF). However, in non-PAF patients, PVI seems to be inadequate and several adjunctive strategies, including ablation of left atrial posterior wall and non-PV triggers, AF mapping and ablation of rotors and drivers, ethanol infusion of vein of Marshall and renal denervation, etc. have been reported with mixed results. Recent trials have also documented the benefits of early rhythm control in preventing cardiovascular events in addition to slowing the progression of PAF to more persistent forms. Similarly, very late relapse of the arrhythmia after successful PVI has drawn attention to the critical role of non-PV triggers and highlighted their relevance as potential ablation targets during repeat procedures. Ablation technology is also under constant evolution with the introduction of non-thermal energy sources and new tools to create durable lesions. This review summarizes the indications, advancements, and future perspective of AF ablation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322413</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae618>10.1093/eurheartj/ehae618</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322413</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Natale</dc:creator>
<dc:creator>Sanghamitra Mohanty</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Elad Anter</dc:creator>
<dc:creator>Ashok Shah</dc:creator>
<dc:creator>Ghaliah Al Mohani</dc:creator>
<dc:creator>Michael Haissaguerre</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Catheter ablation for atrial fibrillation: indications and future perspective</dc:title>
<dc:identifier>pmid:39322413</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae618</dc:identifier>
</item>
<item>
<title>RESPONSE: DEI in the CV Workforce: Foundational for Cardiovascular Care and Critical for Improving Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322331/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1370-1371. doi: 10.1016/j.jacc.2024.07.046.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322331/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322331</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.046>10.1016/j.jacc.2024.07.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322331</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer H Mieres</dc:creator>
<dc:creator>Paul L Douglass</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>RESPONSE: DEI in the CV Workforce: Foundational for Cardiovascular Care and Critical for Improving Outcomes</dc:title>
<dc:identifier>pmid:39322331</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.046</dc:identifier>
</item>
<item>
<title>DEI Is Not Dead: A Framework for Cardiology Fellowship Programs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322330/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1367-1371. doi: 10.1016/j.jacc.2024.07.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322330/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322330</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.042>10.1016/j.jacc.2024.07.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322330</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Amponsah</dc:creator>
<dc:creator>Celina M Yong</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>DEI Is Not Dead: A Framework for Cardiology Fellowship Programs</dc:title>
<dc:identifier>pmid:39322330</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.042</dc:identifier>
</item>
<item>
<title>Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322329/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1342-1362. doi: 10.1016/j.jacc.2024.05.081.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the coexisting chronic kidney disease is advanced, the associated pathophysiologic cardiovascular changes can alter the efficacy and safety of those interventions and complicate the management. This review explores the impact of comorbid advanced heart failure and advanced chronic kidney disease on the efficacy and safety of implantable cardioverter-defibrillator and cardiac resynchronization therapy, the currently available evidence, and potential future directions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322329/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322329</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.081>10.1016/j.jacc.2024.05.081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322329</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Cecilia R Varga</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>William T Abraham</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Francisco Leyva</dc:creator>
<dc:creator>Parta Hatamizadeh</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39322329</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.081</dc:identifier>
</item>
<item>
<title>Are Triglyceride-Rich Lipoprotein ApoB Particles Really 4 Times More Atherogenic Than LDL ApoB Particles?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322328/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1339-1341. doi: 10.1016/j.jacc.2024.07.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322328/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322328</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.033>10.1016/j.jacc.2024.07.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322328</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Allan D Sniderman</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Are Triglyceride-Rich Lipoprotein ApoB Particles Really 4 Times More Atherogenic Than LDL ApoB Particles?</dc:title>
<dc:identifier>pmid:39322328</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.033</dc:identifier>
</item>
<item>
<title>Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL Cholesterol</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TRL/remnants are about 4 times more atherogenic than LDL. Variation in the causal association of non-HDL-C with CHD indicates that adjustment for percentage TRL/remnant-C may be needed for accurate risk prediction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1328-1338. doi: 10.1016/j.jacc.2024.07.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Triglyceride-rich lipoproteins and remnants (TRL/remnants) have a causal, but not yet quantified, relationship with coronary heart disease (CHD): myocardial infarction plus revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to estimate TRL/remnant per-particle atherogenicity, investigate causal relationships with inflammation, and determine whether differences in the atherogenicity of TRL/remnants and low-density lipoprotein (LDL) impact the causal association of non-high-density lipoprotein cholesterol (non-HDL-C) with CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Single nucleotide polymorphisms (SNPs) (N = 1,357) identified by genome-wide association in the UK Biobank were ranked into 10 clusters according to the effect on TRL/remnant-C vs LDL-C. Mendelian randomization analysis was used to estimate for each SNP cluster CHD ORs per 10 mg/dL apolipoprotein B (apoB) and per 0.33 mmol/L non-HDL-cholesterol, and to evaluate association of TRL/remnants with biomarkers of systemic inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SNPs in cluster 1 predominantly affected LDL-C, whereas SNPs in cluster 10 predominantly affected TRL/remnant-C. CHD risk per genetically predicted increase in apoB and in non-HDL-C rose across clusters. ORs per 10 mg/dL higher apoB was 1.15 (95% CI: 1.11-1.19) in cluster 1 vs 1.70 (95% CI: 1.52-1.90) in cluster 10. Comparing ORs between these TRL/remnant-predominant and LDL-predominant clusters, we estimated that TRL/remnants were at least 3.9 (95% CI: 2.8-5.4) times more atherogenic than LDL on a per-particle basis. For non-HDL-C, CHD ORs per 0.33 mmol/L rose from 1.15 (95% CI: 1.11-1.19) for cluster 1 to 1.40 (95% CI: 1.30-1.50) for cluster 10. TRL/remnants exhibited causal relationships with inflammation, but this did not explain their greater atherogenicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TRL/remnants are about 4 times more atherogenic than LDL. Variation in the causal association of non-HDL-C with CHD indicates that adjustment for percentage TRL/remnant-C may be needed for accurate risk prediction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322327</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.034>10.1016/j.jacc.2024.07.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322327</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Elias Björnson</dc:creator>
<dc:creator>Martin Adiels</dc:creator>
<dc:creator>Anders Gummesson</dc:creator>
<dc:creator>Marja-Riitta Taskinen</dc:creator>
<dc:creator>Stephen Burgess</dc:creator>
<dc:creator>Chris J Packard</dc:creator>
<dc:creator>Jan Borén</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL Cholesterol</dc:title>
<dc:identifier>pmid:39322327</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.034</dc:identifier>
</item>
<item>
<title>Can the Excess Cardiovascular Risk Caused by Chronic Kidney Disease Be Canceled Out?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39322326/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240926205110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 1;84(14):1325-1327. doi: 10.1016/j.jacc.2024.06.044.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39322326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240926205110&v=2.18.0.post9+e462414">39322326</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.044>10.1016/j.jacc.2024.06.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39322326</guid>
<pubDate>Wed, 25 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Carmine Zoccali</dc:creator>
<dc:creator>Francesca Mallamaci</dc:creator>
<dc:date>2024-09-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Can the Excess Cardiovascular Risk Caused by Chronic Kidney Disease Be Canceled Out?</dc:title>
<dc:identifier>pmid:39322326</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.044</dc:identifier>
</item>





























</channel>
</rss>